EyePoint Pharmaceutical's Phase 2 PAVIA falls short of primary endpoint
May 11th 2024While it fell short of the primary endpoint of improvement of non-proliferative diabetic retinopathy (NPDR) of at least 2 Diabetic Retinopathy Severity Scale (DRSS) levels as of week 36, DURAVYU did demonstrate stable or improved disease severity with reduced rates of NPDR in 9 months.
Read More
Outdoor artificial light at night may increase the risk of age-related macular degeneration
January 22nd 2024A new case-control study found that older people ages 70 and older living in South Korea’s urban areas were at a significantly higher risk for developing incident exudative age-related macular degeneration.
Read More